跳到主要导航 跳到搜索 跳到主要内容

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

  • Bo Yuan
  • , Jun Zhao
  • , Chengzhi Zhou
  • , Xiumei Wang
  • , Bo Zhu
  • , Minglei Zhuo
  • , Xilin Dong
  • , Jiemei Feng
  • , Cuihua Yi
  • , Yunpeng Yang
  • , Hua Zhang
  • , Wangyan Zhou
  • , Zhengtang Chen
  • , Sheng Yang
  • , Xinghao Ai
  • , Kehe Chen
  • , Xuefan Cui
  • , Difa Liu
  • , Chunmei Shi
  • , Wei Wu
  • Yanjun Zhang, Lianpeng Chang, Jin Li, Rongrong Chen, Shuanying Yang
  • The Second Affiliated Hospital of Xi'an Jiaotong University
  • Peking University
  • The First Affiliated Hospital of Guanzhou Medical University
  • Inner Mongolia Autonomous Region People’s Hospital
  • Xinqiao Hospital
  • Guigang City People's Hospital
  • Qilu Hospital of Shandong University
  • Sun Yat-Sen University Cancer Center
  • Shaanxi Provincial People's Hospital
  • First Affiliated Hospital of University of South China
  • Fujian Medical University
  • Shanghai Jiao Tong University
  • People's Hospital of Guangxi Zhuang Autonomous Region
  • The First Affiliated Hospital with Nanjing Medical University
  • Haian People's Hospital
  • Third Military Medical University
  • Shaanxi Provincial Cancer Hospital
  • Geneplus Beijing Institute

科研成果: 期刊稿件 › 文章 › 同行评审

17 引用 (Scopus)

摘要

Background: Human epidermal growth factor receptor 2 (ERBB2, HER-2) exon 20 insertion (ERBB2ex20ins) remains a refractory oncogenic driver in lung cancer. So far there is limited data showing the co-occurring mutation background of ERBB2ex20ins in Chinese lung cancer and its relationship with response to afatinib. Patients and Methods: A total of 112 Chinese patients with ERBB2ex20ins identified by next-generation sequencing from 17 hospitals were enrolled. The clinical outcomes of 18 patients receiving afatinib treatment were collected. Results: Among the 112 patients, insertion-site subtypes comprised of A775ins (71%; 79/112), G776indel (17%; 19/112), and P780ins (12%; 14/112). There were 66.1% (74/112) of patients carrying TP53 co-mutation and FOXA1 was the most prevalent co-amplified gene (5.5%, 3/55). The co-occurring genomic feature was similar among three insertional-site subtypes and had an overall strong concordance with the western population from the MSKCC cohort (R2 = 0.74, P < 0.01). For the prognosis, patients with co-occurring mutation in cell-cycle pathway especially TP53 showed shorter OS than patients without [median OS: 14.5 m (95% CI:12.7–16.3 m) vs. 30.3 m (95% CI: not reached), p = 0.04], while the OS was comparable among three subtypes. For the response to afatinib, ERBB2ex20ins as a subclonal variant was an independent factor relating to shorter PFS [median PFS: 1.2 m (95% CI: 0.8–1.6 m) vs. 4.3 m (95% CI: 3.3–5.3 m), p < 0.05]. Conclusion: Our data revealed co-occurring TP53 represent an unfavorable prognosis of patients with ERBB2ex20ins, emphasizing the more valuable role of the co-mutation patterns than insertion-site subtypes in predicting prognosis of this group of patients. Moreover, the clonality status of ERBB2ex20ins was identified as a potential indicator for response to afatinib.

源语言英语
期刊论文编号729
期刊Frontiers in Oncology
卷10
DOI
出版状态已出版 - 12 5月 2020
已对外发布是

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

学术指纹

探究 'Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib' 的科研主题。它们共同构成独一无二的学术指纹。

引用此